Sign In
Buy AMPH
$18.12
-0.330 (-1.79%)
At Close: Jun 03, 2026
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
04:05pm, Wednesday, 07'th Aug 2024
Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 7, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
04:05pm, Wednesday, 31'st Jul 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, af
Why Amphastar (AMPH) is Poised to Beat Earnings Estimates Again
01:11pm, Monday, 15'th Jul 2024
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
01:21pm, Wednesday, 10'th Jul 2024
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
7 Biotech Stocks to Buy on the Dip: June 2024
12:56pm, Monday, 24'th Jun 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
07:20am, Tuesday, 18'th Jun 2024
Will the market get interest rate cuts at all this year? That is the question that looms over most investors' shoulders today.
BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC
04:30pm, Friday, 14'th Jun 2024
TROY, Mich. , June 14, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) as its "St
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
06:00am, Tuesday, 04'th Jun 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increas
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
06:00am, Monday, 03'rd Jun 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will par
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
02:06am, Thursday, 30'th May 2024
Seeking Alpha's screener identified Amphastar Pharmaceuticals as a potential investment candidate based on its solid financials, positive growth in revenue and earnings. Despite its strong financials
Amphastar Pharmaceuticals: Profitable Pharma With Strong Growth
05:29am, Monday, 20'th May 2024
Amphastar Pharmaceuticals is a small-cap pharmaceutical company focused on developing and selling injectable, inhalation, and intranasal products. The company reported a 29% increase in net revenues i
Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade
06:15am, Thursday, 16'th May 2024
Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden a
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2024 Earnings Call Transcript
11:11pm, Wednesday, 08'th May 2024
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Pet
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
06:16pm, Wednesday, 08'th May 2024
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.62 per share a year ago.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
04:05pm, Wednesday, 08'th May 2024
Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 8, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Co
